OncoMatch/Clinical Trials/NCT06773845
Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria
Is NCT06773845 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies TheraSphere for hepatocellular carcinoma (hcc).
Treatment: TheraSphere — At four major centers in Korea, patients with hepatocellular carcinoma (HCC) that exceed the up-to-7 criteria yet remain locally confined will undergo ablative radioembolization using Yttrium-90 glass microspheres, guided by a standardized dosimetry method. Their treatment response, survival outcomes, and adverse events will be monitored for two years following the procedure.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Leukocytes ≥ 2,000/µL and ≤ 15,000/µL; Hemoglobin ≥ 8.0 g/dL (transfusion allowed); Platelet ≥ 40,000/µL; INR ≤ 2.0 for patients not taking anticoagulants
Kidney function
Creatinine ≤ 2.5 mg/dL
Liver function
Total bilirubin ≤ 2.0 mg/dL; AST ≤ 200 IU/L (≤ 5X upper normal limit); ALT ≤ 200 IU/L (≤ 5X upper normal limit)
No major organ dysfunction according to blood test performed within two months of study enrollment: * Leukocytes ≥ 2,000/µL and ≤ 15,000/µL * Hemoglobin ≥ 8.0 g/dL (transfusion allowed to meet this criterion) * Total bilirubin ≤ 2.0 mg/dL * Platelet ≥ 40,000/µL * International normalized ratio (INR) ≤ 2.0 for patients not taking anticoagulants * Aspartate transaminase (AST) ≤ 200 IU/L (i.e., ≤ 5X upper normal limit) * Alanine transaminase (ALT) ≤ 200 IU/L (i.e., ≤ 5X upper normal limit) * Creatinine ≤ 2.5 mg/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify